Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Exact Sciences

Explore full profile

Developer and manufacturer of cologuard, a non-invasive screening test for the early detection of colorectal cancer

Madison, United StatesFounded 1995Biotech & Life Sciences
Valuation $22B Market cap · Mar/2026
Revenue $3.25B Latest reported FY
EBITDA $18M Latest reported FY

At a glance

Status
Listed
Founded
1995
Headquarters
Madison, United States
Listing
IPO 2001
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later1 investor entered at this stage

  • Johns Hopkins University

Talent

Book a demo to see the people
Employees mapped 5,265 incl. 45 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 20 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Alumni founders

4 startups

Former Exact Sciences employees who went on to found companies, sorted by Dealroom signal score.

Tessera TherapeuticsEst. 2018
Noubar AfeyanUnited States
Signal score63
Predictive BiosciencesEst. 2006
ASAnthony P. ShuberUnited States
Signal score60
SynapDxEst. 2010
Jeffery LuberUnited States
Signal score58
Gregor DiagnosticsEst. 2016
Tobias ZutzUnited States
Signal score55
Explore the full alumni networkBook a demo

Global footprint

Workforce and web traffic by country
Workforce by country
26 countries with
team presence
🇺🇸 United States93.1%
🇨🇭 Switzerland1.3%
🇵🇱 Poland1.2%
🇩🇪 Germany0.7%
🇬🇧 United Kingdom0.7%
Top 5 of 26 shown
Web traffic by country
780K monthly visits
across markets
🇺🇸 United States94.9%
🇮🇳 India0.9%
🇨🇦 Canada0.5%
🇯🇵 Japan0.4%
🇲🇽 Mexico0.4%
Top 5 markets shown

Patents

Estimated portfolio value
$313M

121 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Exact Sciences was the backer or acquirer, 2017–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

55 deals across Exact Sciences's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Exact Sciences deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Exact Sciences's portfolio, mapped.

        Stage
        Period
        55 of 55 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Exact Sciences on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Exact Sciences on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles